coaprovel
sanofi winthrop industrie - irbesartan, hydrochlorothiazide - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension. this fixed dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone.
coaprovel 150mg/12.5mg tablet
sanofi-aventis (malaysia) sdn. bhd. - irbesartan; hydrochlorothiazide -
coaprovel 300mg/12.5mg tablet
sanofi-aventis (malaysia) sdn. bhd. - hydrochlorothiazide; irbesartan -
coaprovel 300/25mg tablet
sanofi-aventis (malaysia) sdn. bhd. - hydrochlorothiazide; irbesartan -
coaprovel film-coated tablet 30025mg
sanofi-aventis singapore pte. ltd. - hydrochlorothiazide; irbesartan - tablet, film coated - 25.00mg - hydrochlorothiazide 25.00mg; irbesartan 300.00mg
coaprovel film-coated tablet 15012.5 mg
sanofi-aventis singapore pte. ltd. - hydrochlorothiazide; irbesartan - tablet, film coated - 12.50 mg - hydrochlorothiazide 12.50 mg; irbesartan 150.00 mg
coaprovel film-coated tablet 30012.5 mg
sanofi-aventis singapore pte. ltd. - hydrochlorothiazide; irbesartan - tablet, film coated - 12.50 mg - hydrochlorothiazide 12.50 mg; irbesartan 300.00 mg
aprovel film-coated tablet 75 mg
sanofi-aventis singapore pte. ltd. - irbesartan - tablet, film coated - 75.00 mg
aprovel 150 mg
aventis pharma (pty) limited - irbesartan - tablets - irbesartan tablet, 150 mg
aprovel 300 mg
aventis pharma (pty) limited - irbesartan - tablets - irbesartan tablet, 300 mg